JPWO2021222771A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021222771A5
JPWO2021222771A5 JP2022566201A JP2022566201A JPWO2021222771A5 JP WO2021222771 A5 JPWO2021222771 A5 JP WO2021222771A5 JP 2022566201 A JP2022566201 A JP 2022566201A JP 2022566201 A JP2022566201 A JP 2022566201A JP WO2021222771 A5 JPWO2021222771 A5 JP WO2021222771A5
Authority
JP
Japan
Prior art keywords
patient
fluid injection
experience
probability
risk prediction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566201A
Other languages
Japanese (ja)
Other versions
JP2023523798A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030210 external-priority patent/WO2021222771A1/en
Publication of JP2023523798A publication Critical patent/JP2023523798A/en
Publication of JPWO2021222771A5 publication Critical patent/JPWO2021222771A5/ja
Pending legal-status Critical Current

Links

Claims (21)

システムであって、
少なくとも1つのプロセッサを備え、前記プロセッサは、
患者に関連する患者データを取得することと、
前記患者データに基づいて、前記患者に施される流体注入に関連する前記患者の初期リスク予測を決定することであって、前記初期リスク予測は、前記患者が前記流体注入に応答して少なくとも1つの有害事象を経験する確率を含み、前記初期リスク予測が、前記患者が血管外漏出を経験する確率、前記患者が造影後急性腎傷害を経験する確率、前記患者が急性有害事象を経験する確率、前記患者が造影剤誘発腎毒性を経験する確率、および前記患者が甲状腺中毒症を経験する確率を含むように、前記少なくとも1つの有害事象は、前記血管外漏出、前記造影後急性腎傷害、前記急性有害事象、前記造影剤誘発腎毒性、および前記甲状腺中毒症の有害事象を含む、決定することと、
前記流体注入が前記患者に施される前に、前記初期リスク予測をユーザデバイスに提供することであって、前記初期リスク予測は、前記流体注入の前に患者に薬剤を投与するためのプロンプト、前記流体注入のための注入プロトコルを調整するためのプロンプト、撮像スキャンのための撮像プロトコルを調整するためのプロンプト、前記流体注入の前に患者を準備するためのプロンプト、前記流体注入の後に前記患者を観察および／もしくはフォローアップするためのプロンプト、またはそれらの任意の組み合わせのうちの少なくとも1つをさらに含む、提供することと、
前記患者に関連するセンサデータであって、前記流体注入が開始された後に決定された、センサデータを取得することと、
前記流体注入が開始された後に決定された前記センサデータに基づいて、前記流体注入に関連する前記患者の現在のリスク予測を決定することであって、前記現在のリスク予測は、前記患者が前記流体注入に応答して前記少なくとも1つの有害事象を経験する確率を含む、決定することと、
前記現在のリスク予測を前記ユーザデバイスに提供することと、
を行うようにプログラムおよび／または構成されている、システム。 1. A system comprising:
At least one processor, the processor comprising:
Obtaining patient data associated with a patient;
determining an initial risk prediction for the patient associated with a fluid injection administered to the patient based on the patient data, the initial risk prediction comprising a probability that the patient will experience at least one adverse event in response to the fluid injection, the at least one adverse event comprising the extravasation, the post-contrast acute kidney injury, the acute adverse event, the contrast induced nephrotoxicity, and the thyrotoxicosis adverse event, such that the initial risk prediction comprises a probability that the patient will experience extravasation, a probability that the patient will experience post-contrast acute kidney injury, a probability that the patient will experience an acute adverse event, a probability that the patient will experience contrast induced nephrotoxicity, and a probability that the patient will experience thyrotoxicosis;
providing the initial risk prediction to a user device before the fluid injection is administered to the patient , the initial risk prediction further comprising at least one of a prompt to administer medication to the patient before the fluid injection, a prompt to adjust an injection protocol for the fluid injection, a prompt to adjust an imaging protocol for an imaging scan, a prompt to prepare a patient before the fluid injection, a prompt to observe and/or follow up with the patient after the fluid injection, or any combination thereof;
acquiring sensor data associated with the patient, the sensor data being determined after the fluid injection has been initiated;
determining a current risk prediction for the patient associated with the fluid infusion based on the sensor data determined after the fluid infusion has been initiated, the current risk prediction including a probability that the patient will experience the at least one adverse event in response to the fluid infusion;
providing the current risk prediction to the user device; and
A system programmed and/or configured to: 前記少なくとも1つのプロセッサは、
前記現在のリスク予測に基づいて、（i）前記流体注入を停止する流体注入システム、および（ii）撮像動作のタイミングを調整する撮像システムのうちの少なくとも1つを自動的に制御すること
を行うようにさらにプログラムおよび／または構成されている、請求項1に記載のシステム。 The at least one processor:
13. The system of claim 1, further programmed and/or configured to automatically control at least one of: (i) a fluid injection system to stop the fluid injection; and (ii) an imaging system to adjust timing of imaging operations based on the current risk prediction. 前記患者データは、前記患者に関連する以下のパラメータ、すなわち、年齢、性別、体重、以前の化学療法状態、推定糸球体濾過量（eGFR）、甲状腺刺激ホルモン（TSH）レベル、トリヨードサイロニン（FT3）チロキシン（FT4）比（FT3／FT4）、環境影響のレベル、以前の流体注入状態に対する事前反応、アトピー性疾患状態、糖尿病および高血圧のうちの少なくとも1つに関連する医療状態、鬱血性心不全状態、ヘマトクリットレベル、腎不全状態、悪性腫瘍状態、中心静脈アクセス状態のための埋込デバイス、薬剤の種類、前記流体注入において投与される流体媒体の種類、流体注入に関連する注入プロトコル、画像検査の種類、前記流体注入に関連する流速、前記流体注入に関連するカテーテルゲージ、前記流体注入に関連する流体の総体積、前記流体注入に関連する圧力曲線、流体注入に関連する圧力限界曲線、前記流体注入に関連する注入部位場所、またはそれらの任意の組み合わせのうちの少なくとも1つを含む、請求項1に記載のシステム。 The system of claim 1, wherein the patient data includes at least one of the following parameters associated with the patient: age, sex, weight, previous chemotherapy status, estimated glomerular filtration rate (eGFR), thyroid stimulating hormone (TSH) level, triiodothyronine (FT3) thyroxine (FT4) ratio (FT3/FT4), level of environmental influence, prior response to previous fluid infusion status, atopic disease status, medical status associated with at least one of diabetes and hypertension, congestive heart failure status, hematocrit level, renal failure status, malignancy status, implanted device for central venous access status, type of medication, type of fluid medium administered in the fluid infusion, infusion protocol associated with the fluid infusion, type of imaging test, flow rate associated with the fluid infusion, catheter gauge associated with the fluid infusion, total volume of fluid associated with the fluid infusion, pressure curve associated with the fluid infusion, pressure limit curve associated with the fluid infusion, infusion site location associated with the fluid infusion, or any combination thereof. 前記センサデータは、前記患者に関連する以下のパラメータ、すなわち、心拍数、音もしくは振動、温度、酸素飽和度、心電図(ECG)、体脂肪／水分比、組織インピーダンス、血管分布レベル、血管径、水和レベル、ヘマトクリットレベル、皮膚抵抗率、血圧、筋張力レベル、光吸収率レベル、運動レベル、腕の位置、腕の周囲、呼吸数、放射線吸収量、筋電図(EMG)、皮膚の色、表面血管拡張量、生体インピーダンス、光吸収率、ヘモグロビンレベル、炎症レベル、前記患者の周囲の環境の環境温度、前記患者の周囲の前記環境の気圧、周囲光レベル、周囲音レベル、またはそれらの任意の組み合わせのうちの少なくとも1つを含む、請求項1に記載のシステム。 2. The system of claim 1, wherein the sensor data includes at least one of the following parameters associated with the patient: heart rate, sound or vibration, temperature, oxygen saturation, electrocardiogram ( ECG ) , body fat/water ratio, tissue impedance, vascularity level, vascular diameter, hydration level, hematocrit level, skin resistivity, blood pressure, muscle tension level, light absorptance level, exercise level, arm position, arm circumference, respiratory rate, radiation absorption, electromyogram ( EMG ) , skin color, surface vasodilation, bioimpedance, light absorptance, hemoglobin level, inflammation level, ambient temperature of an environment surrounding the patient, air pressure of the environment surrounding the patient, ambient light level, ambient sound level, or any combination thereof. 前記流体注入が開始された後に、前記患者に関連する前記センサデータを決定するように構成された少なくとも1つのセンサ
をさらに備える、請求項1に記載のシステム。 The system of claim 1 , further comprising: at least one sensor configured to determine the sensor data associated with the patient after the fluid injection is initiated. 前記少なくとも1つのセンサは、
前記流体注入後に前記センサデータを決定するようにさらに構成され、
前記少なくとも1つのプロセッサは、
前記流体注入後に決定された前記センサデータに基づいて、前記現在のリスク予測を決定することと、
前記流体注入後に、前記現在のリスク予測を前記ユーザデバイスに提供することと、
を行うようにさらにプログラムおよび／または構成されている、請求項5に記載のシステム。 The at least one sensor includes:
further configured to determine the sensor data after the fluid injection;
The at least one processor:
determining the current risk prediction based on the sensor data determined after the fluid injection;
providing the current risk prediction to the user device after the fluid injection;
The system of claim 5 , further programmed and/or configured to: 前記少なくとも1つの有害事象は、前記血管外漏出を含み、前記少なくとも1つのプロセッサは、前記患者が前記血管外漏出を経験していると判定したことに応答して、流体注入システムを自動的に制御して前記流体注入を停止することによって前記現在のリスク予測を提供するようにさらにプログラムおよび／または構成されている、請求項5に記載のシステム。 The system of claim 5, wherein the at least one adverse event includes an extravasation , and the at least one processor is further programmed and/or configured to provide the current risk prediction by automatically controlling a fluid injection system to stop the fluid injection in response to determining that the patient is experiencing the extravasation. 前記少なくとも1つのセンサは、以下のセンサ、すなわち、画像捕捉デバイス；加速度計；歪みゲージ；全地球測位システム（GPS）；皮膚抵抗率またはコンダクタンスセンサ；心拍数モニタ；マイクロフォン；熱センサまたは温度センサ；パルスオキシメータ；水和センサ；線量計；超音波センサ；音響センサ；組織インピーダンス、筋電図（EMG）、および心電図（ECG）のうちの少なくとも1つを測定するように構成された1または複数の電極；マイクロ波センサ；機械インピーダンスセンサ；化学センサ；力センサまたは圧力センサ；あるいはそれらの任意の組み合わせのうちの少なくとも1つを含む、請求項5に記載のシステム。 6. The system of claim 5, wherein the at least one sensor includes at least one of the following sensors: an image capture device; an accelerometer; a strain gauge; a global positioning system (GPS); a skin resistivity or conductance sensor; a heart rate monitor; a microphone; a thermal or temperature sensor; a pulse oximeter; a hydration sensor; a dosimeter; an ultrasonic sensor; an acoustic sensor; one or more electrodes configured to measure at least one of tissue impedance, an electromyogram (EMG), and an electrocardiogram (ECG); a microwave sensor; a mechanical impedance sensor; a chemical sensor; a force or pressure sensor; or any combination thereof. システムであって、
患者に関連する流体注入が開始される前に、前記患者に関連するセンサデータを決定するように構成された少なくとも1つのセンサと、
少なくとも1つのプロセッサであって、
前記患者に関連する患者データを取得することと、
前記患者データおよび前記センサデータに基づいて、前記患者に施される流体注入に関連する前記患者の初期リスク予測を決定することであって、前記初期リスク予測は、前記患者が前記流体注入に応答して少なくとも1つの有害事象を経験する確率を含み、前記初期リスク予測が、前記患者が血管外漏出を経験する確率、前記患者が造影後急性腎傷害を経験する確率、前記患者が急性有害事象を経験する確率、前記患者が造影剤誘発腎毒性を経験する確率、および前記患者が甲状腺中毒症を経験する確率を含むように、前記少なくとも1つの有害事象は、前記血管外漏出、前記造影後急性腎傷害、前記急性有害事象、前記造影剤誘発腎毒性、および前記甲状腺中毒症の有害事象を含む、決定することと、
前記流体注入が前記患者に施される前に、前記初期リスク予測をユーザデバイスに提供することであって、前記初期リスク予測は、前記流体注入の前に患者に薬剤を投与するためのプロンプト、前記流体注入のための注入プロトコルを調整するためのプロンプト、撮像スキャンのための撮像プロトコルを調整するためのプロンプト、前記流体注入の前に患者を準備するためのプロンプト、前記流体注入の後に前記患者を観察および／もしくはフォローアップするためのプロンプト、またはそれらの任意の組み合わせのうちの少なくとも1つをさらに含む、提供することと、
を行うようにプログラムおよび／または構成された、少なくとも1つのプロセッサと、
を備える、システム。 1. A system comprising:
at least one sensor configured to determine sensor data associated with a patient before a fluid infusion associated with the patient is initiated;
at least one processor,
obtaining patient data associated with the patient;
determining an initial risk prediction for the patient associated with a fluid injection administered to the patient based on the patient data and the sensor data, the initial risk prediction including a probability that the patient will experience at least one adverse event in response to the fluid injection, the at least one adverse event including the extravasation, the post-contrast acute kidney injury, the acute adverse event, the contrast induced nephrotoxicity, and the thyrotoxicosis adverse event, such that the initial risk prediction includes a probability that the patient will experience extravasation, a probability that the patient will experience post-contrast acute kidney injury, a probability that the patient will experience an acute adverse event, a probability that the patient will experience contrast induced nephrotoxicity, and a probability that the patient will experience thyrotoxicosis;
providing the initial risk prediction to a user device before the fluid injection is administered to the patient , the initial risk prediction further comprising at least one of a prompt to administer medication to the patient before the fluid injection, a prompt to adjust an injection protocol for the fluid injection, a prompt to adjust an imaging protocol for an imaging scan, a prompt to prepare a patient before the fluid injection, a prompt to observe and/or follow up with the patient after the fluid injection, or any combination thereof;
At least one processor programmed and/or configured to:
A system comprising: システムであって、
患者に関連する流体注入が開始された後に、前記患者に関連するセンサデータを決定するように構成された少なくとも1つのセンサと、
少なくとも1つのプロセッサであって、
前記流体注入が開始された後に決定された前記センサデータに基づいて、前記流体注入に関連する前記患者の現在のリスク予測を決定することであって、前記現在のリスク予測は、前記患者が前記流体注入に応答して少なくとも1つの有害事象を経験する確率を含み、前記現在のリスク予測が、前記患者が血管外漏出を経験する確率、前記患者が造影後急性腎傷害を経験する確率、前記患者が急性有害事象を経験する確率、前記患者が造影剤誘発腎毒性を経験する確率、および前記患者が甲状腺中毒症を経験する確率を含むように、前記少なくとも1つの有害事象は、前記血管外漏出、前記造影後急性腎傷害、前記急性有害事象、前記造影剤誘発腎毒性、および前記甲状腺中毒症の有害事象を含む、決定することと、
前記現在のリスク予測をユーザデバイスに提供することと、
を行うようにプログラムおよび／または構成された、少なくとも1つのプロセッサと、
を備え、
前記少なくとも1つのプロセッサが、前記患者が前記血管外漏出を経験するとの決定に応答して、流体注入システムが前記流体注入を停止するように自動的に制御することにより、前記現在のリスク予測を提供するようにさらにプログラムおよび／または構成されている、システム。 1. A system comprising:
at least one sensor configured to determine sensor data associated with a patient after a fluid infusion associated with the patient has been initiated;
at least one processor,
determining a current risk prediction for the patient associated with the fluid injection based on the sensor data determined after the fluid injection has been initiated, the current risk prediction including a probability that the patient will experience at least one adverse event in response to the fluid injection, the at least one adverse event including the extravasation, the post-contrast acute kidney injury, the acute adverse event, the contrast induced nephrotoxicity, and the thyrotoxicosis adverse event, such that the current risk prediction includes a probability that the patient will experience extravasation, a probability that the patient will experience post-contrast acute kidney injury, a probability that the patient will experience an acute adverse event, a probability that the patient will experience contrast induced nephrotoxicity, and a probability that the patient will experience thyrotoxicosis;
providing the current risk prediction to a user device; and
At least one processor programmed and/or configured to:
Equipped with
The system, wherein the at least one processor is further programmed and/or configured to provide the current risk prediction by automatically controlling a fluid injection system to stop the fluid injection in response to a determination that the patient will experience the extravasation. システムであって、
少なくとも1つのプロセッサを備え、前記プロセッサは、
患者に関連するセンサデータであって、前記患者に関連する流体注入が開始された後に決定された、センサデータを取得することと、
前記流体注入が開始された後に決定された前記センサデータに基づいて、前記流体注入に関連する前記患者の現在のリスク予測を決定することであって、前記現在のリスク予測は、前記患者が前記流体注入に応答して少なくとも1つの有害事象を経験する確率を含み、前記現在のリスク予測が、前記患者が血管外漏出を経験する確率、前記患者が造影後急性腎傷害を経験する確率、前記患者が急性有害事象を経験する確率、前記患者が造影剤誘発腎毒性を経験する確率、および前記患者が甲状腺中毒症を経験する確率を含むように、前記少なくとも1つの有害事象は、前記血管外漏出、前記造影後急性腎傷害、前記急性有害事象、前記造影剤誘発腎毒性、および前記甲状腺中毒症の有害事象を含む、決定することと、
前記現在のリスク予測をユーザデバイスに提供することと、
前記現在のリスク予測に基づいて、（i）前記流体注入を停止する流体注入システム、および（ii）撮像動作のタイミングを調整する撮像システムのうちの少なくとも1つを自動的に制御することと、
を行うようにプログラムおよび／または構成されている、システム。 1. A system comprising:
At least one processor, the processor comprising:
acquiring sensor data associated with a patient, the sensor data being determined after a fluid infusion associated with the patient has been initiated;
determining a current risk prediction for the patient associated with the fluid injection based on the sensor data determined after the fluid injection has been initiated, the current risk prediction comprising a probability that the patient will experience at least one adverse event in response to the fluid injection, the at least one adverse event comprising the extravasation, the post-contrast acute kidney injury, the acute adverse event, the contrast induced nephrotoxicity, and the thyrotoxicosis adverse event, such that the current risk prediction comprises a probability that the patient will experience extravasation, a probability that the patient will experience post-contrast acute kidney injury, a probability that the patient will experience an acute adverse event, a probability that the patient will experience contrast induced nephrotoxicity, and a probability that the patient will experience thyrotoxicosis;
providing the current risk prediction to a user device; and
automatically controlling at least one of (i) a fluid injection system to stop the fluid injection and (ii) an imaging system to adjust timing of imaging operations based on the current risk prediction;
A system programmed and/or configured to: システムであって、
少なくとも1つのプロセッサであって、
アプリケーションプログラムインターフェース（API）を介して、少なくとも1つのユーザデバイスに、患者に施される流体注入に関連する情報を提供することと、
前記APIを介して、前記少なくとも1つのユーザデバイスから、前記流体注入の前に、前記患者に関連する患者データを受信することであって、前記患者データは、前記流体注入に関連する少なくとも1つの患者嗜好を含み、少なくとも1つの患者データは、流体注入の間に前記患者が少なくとも1つの有害事象を経験する確率を評価するためのリスク予測に使用され、前記リスク予測が、前記患者が血管外漏出を経験する確率、前記患者が造影後急性腎傷害を経験する確率、前記患者が急性有害事象を経験する確率、前記患者が造影剤誘発腎毒性を経験する確率、および前記患者が甲状腺中毒症を経験する確率を含むように、前記少なくとも1つの有害事象は、前記血管外漏出、前記造影後急性腎傷害、前記急性有害事象、前記造影剤誘発腎毒性、および前記甲状腺中毒症の有害事象を含む、受信することと、
を行うようにプログラムおよび／または構成されている少なくとも1つのプロセッサと、
流体インジェクタおよび医療用撮像装置のうちの少なくとも1つと
を備え、
前記流体注入の注入プロトコルおよび前記医療用撮像装置の撮像プロトコルのうちの少なくとも1つのパラメータが、前記少なくとも1つの患者データに基づいて調整される、システム。 1. A system comprising:
at least one processor,
providing, via an application program interface (API), to at least one user device, information related to a fluid infusion to be administered to a patient;
receiving, via the API, from the at least one user device, patient data related to the patient prior to the fluid injection, the patient data including at least one patient preference related to the fluid injection, the at least one patient data being used in a risk prediction to assess a probability that the patient will experience at least one adverse event during the fluid injection , the at least one adverse event including the extravasation, the post-contrast acute kidney injury, the acute adverse event, the contrast induced nephrotoxicity, and the thyrotoxicosis adverse event, such that the risk prediction includes a probability that the patient will experience extravasation, a probability that the patient will experience post-contrast acute kidney injury, a probability that the patient will experience an acute adverse event, a probability that the patient will experience contrast induced nephrotoxicity, and a probability that the patient will experience thyrotoxicosis ;
At least one processor programmed and/or configured to :
at least one of a fluid injector and a medical imaging device;
Equipped with
A system , wherein at least one parameter of an injection protocol of the fluid injection and an imaging protocol of the medical imaging device is adjusted based on the at least one patient data. 方法であって、
少なくとも1つのプロセッサを用いて、患者に関連する患者データを取得するステップと、
前記少なくとも1つのプロセッサを用いて、前記患者データに基づいて、前記患者に施される流体注入に関連する前記患者の初期リスク予測を決定するステップであって、前記初期リスク予測は、前記患者が前記流体注入に応答して少なくとも1つの有害事象を経験する確率を含み、前記初期リスク予測が、前記患者が血管外漏出を経験する確率、前記患者が造影後急性腎傷害を経験する確率、前記患者が急性有害事象を経験する確率、前記患者が造影剤誘発腎毒性を経験する確率、および前記患者が甲状腺中毒症を経験する確率を含むように、前記少なくとも1つの有害事象は、前記血管外漏出、前記造影後急性腎傷害、前記急性有害事象、前記造影剤誘発腎毒性、および前記甲状腺中毒症の有害事象を含む、ステップと、
前記少なくとも1つのプロセッサを用いて、前記流体注入が前記患者に施される前に、前記初期リスク予測をユーザデバイスに提供するステップと、
少なくとも1つのセンサを用いて、前記流体注入が開始された後に、前記患者に関連するセンサデータを決定するステップと、
前記少なくとも1つのプロセッサを用いて、前記流体注入が開始された後に決定された前記センサデータに基づいて、前記流体注入に関連する前記患者の現在のリスク予測を決定するステップであって、前記現在のリスク予測は、前記患者が前記流体注入に応答して前記少なくとも1つの有害事象を経験する確率を含む、ステップと、
前記少なくとも1つのプロセッサを用いて、前記現在のリスク予測を前記ユーザデバイスに提供するステップであって、前記初期リスク予測は、前記流体注入の前に患者に薬剤を投与するためのプロンプト、前記流体注入のための注入プロトコルを調整するためのプロンプト、撮像スキャンのための撮像プロトコルを調整するためのプロンプト、前記流体注入の前に患者を準備するためのプロンプト、前記流体注入の後に前記患者を観察および／もしくはフォローアップするためのプロンプト、またはそれらの任意の組み合わせのうちの少なくとも1つをさらに含む、ステップと、
を含む、方法。 1. A method comprising:
acquiring, with at least one processor, patient data associated with the patient;
determining with the at least one processor an initial risk prediction for the patient associated with a fluid injection administered to the patient based on the patient data, the initial risk prediction including a probability that the patient will experience at least one adverse event in response to the fluid injection, the at least one adverse event including the extravasation, the post-contrast acute kidney injury, the acute adverse event, the contrast induced nephrotoxicity, and the thyrotoxicosis adverse event, such that the initial risk prediction includes a probability that the patient will experience extravasation, a probability that the patient will experience post-contrast acute kidney injury, a probability that the patient will experience an acute adverse event, a probability that the patient will experience contrast induced nephrotoxicity, and a probability that the patient will experience thyrotoxicosis;
providing, with the at least one processor, the initial risk prediction to a user device before the fluid injection is administered to the patient;
determining, using at least one sensor, sensor data associated with the patient after the fluid injection is initiated;
determining, with the at least one processor, a current risk prediction for the patient associated with the fluid infusion based on the sensor data determined after the fluid infusion has been initiated, the current risk prediction comprising a probability that the patient will experience the at least one adverse event in response to the fluid infusion;
providing, with the at least one processor, the current risk prediction to the user device, wherein the initial risk prediction further includes at least one of a prompt to administer medication to a patient prior to the fluid injection, a prompt to adjust an injection protocol for the fluid injection, a prompt to adjust an imaging protocol for an imaging scan, a prompt to prepare a patient prior to the fluid injection, a prompt to observe and/or follow up with the patient after the fluid injection, or any combination thereof;
A method comprising: 前記患者データは、前記患者に関連する以下のパラメータ、すなわち、年齢、性別、体重、以前の化学療法状態、推定糸球体濾過量（eGFR）、甲状腺刺激ホルモン（TSH）レベル、トリヨードサイロニン（FT3）チロキシン（FT4）比（FT3／FT4）、環境影響のレベル、以前の流体注入状態に対する事前反応、アトピー性疾患状態、糖尿病および高血圧のうちの少なくとも1つに関連する医療状態、鬱血性心不全状態、ヘマトクリットレベル、腎不全状態、悪性腫瘍状態、中心静脈アクセス状態のための埋込デバイス、薬剤の種類、前記流体注入において投与される流体媒体の種類、前記流体注入の種類、画像検査の種類、前記流体注入に関連する流速、前記流体注入に関連するカテーテルゲージ、前記流体注入に関連する流体の総体積、前記流体注入に関連する圧力曲線、前記流体注入に関連する注入部位場所、またはそれらの任意の組み合わせのうちの少なくとも1つを含む、請求項13に記載の方法。 14. The method of claim 13, wherein the patient data comprises at least one of the following parameters associated with the patient: age, sex, weight, previous chemotherapy status, estimated glomerular filtration rate (eGFR), thyroid stimulating hormone (TSH) level, triiodothyronine (FT3) thyroxine (FT4) ratio (FT3/FT4), level of environmental influence, prior response to previous fluid infusion status, atopic disease status, medical status associated with at least one of diabetes and hypertension, congestive heart failure status, hematocrit level, renal failure status, malignancy status, implanted device for central venous access status, type of medication, type of fluid medium administered in the fluid infusion, type of the fluid infusion, type of imaging test, flow rate associated with the fluid infusion, catheter gauge associated with the fluid infusion, total volume of fluid associated with the fluid infusion, pressure curve associated with the fluid infusion, infusion site location associated with the fluid infusion, or any combination thereof. 前記少なくとも1つの有害事象は、血管外漏出、造影後急性腎傷害、急性有害事象、造影剤誘発腎毒性、甲状腺中毒症、またはそれらの任意の組み合わせの有害事象のうちの少なくとも1つを含む、請求項13に記載の方法。 14. The method of claim 13, wherein the at least one adverse event comprises at least one of the following adverse events: extravasation, post-contrast acute kidney injury, an acute adverse event, contrast-induced nephrotoxicity, thyrotoxicosis, or any combination thereof. 前記センサデータは、前記患者に関連する以下のパラメータ、すなわち、心拍数、音もしくは振動、温度、酸素飽和度、心電図(ECG)、体脂肪／水分比、組織インピーダンス、血管分布レベル、血管径、水和レベル、ヘマトクリットレベル、皮膚抵抗率、血圧、筋張力レベル、光吸収率レベル、運動レベル、腕の位置、腕の周囲、呼吸数、放射線吸収量、筋電図(EMG)、皮膚の色、表面血管拡張量、生体インピーダンス、光吸収率、ヘモグロビンレベル、炎症レベル、前記患者の周囲の環境の環境温度、前記患者の周囲の環境の気圧、周囲光レベル、周囲音レベル、またはそれらの任意の組み合わせのうちの少なくとも1つを含む、請求項13に記載の方法。 14. The method of claim 13, wherein the sensor data includes at least one of the following parameters associated with the patient: heart rate, sound or vibration, temperature, oxygen saturation, electrocardiogram ( ECG ) , body fat/water ratio, tissue impedance, vascularity level, vascular diameter, hydration level, hematocrit level, skin resistivity, blood pressure, muscle tension level, light absorptance level, exercise level, arm position, arm circumference, respiratory rate, radiation absorption, electromyogram ( EMG ) , skin color, surface vasodilation, bioimpedance, light absorptance, hemoglobin level, inflammation level, ambient temperature of an environment surrounding the patient, air pressure of an environment surrounding the patient, ambient light level, ambient sound level, or any combination thereof. 前記少なくとも1つのセンサを用いて、前記流体注入の間に前記センサデータを決定するステップと、
前記少なくとも1つのプロセッサを用いて、前記流体注入の間に決定された前記センサデータに基づいて、前記流体注入に関連する前記患者の前記現在のリスク予測を決定するステップと、
前記流体注入の間に、前記現在のリスク予測を前記ユーザデバイスに提供するステップと、
をさらに含む、請求項13に記載の方法。 determining said sensor data during said fluid injection using said at least one sensor;
determining, with the at least one processor, the current risk prediction for the patient associated with the fluid injection based on the sensor data determined during the fluid injection;
providing the current risk prediction to the user device during the fluid injection;
14. The method of claim 13 , further comprising: 前記少なくとも1つのセンサを用いて、前記流体注入の後に前記センサデータを決定するステップと、
前記少なくとも1つのプロセッサを用いて、前記流体注入の後に決定された前記センサデータに基づいて、前記流体注入に関連する前記患者の前記現在のリスク予測を決定するステップと、
前記流体注入の後に、前記現在のリスク予測を前記ユーザデバイスに提供するステップと、
をさらに含む、請求項13に記載の方法。 determining said sensor data after said fluid injection using said at least one sensor;
determining, with the at least one processor, the current risk prediction for the patient associated with the fluid injection based on the sensor data determined after the fluid injection;
providing the current risk prediction to the user device after the fluid injection;
14. The method of claim 13 , further comprising: 前記少なくとも1つの有害事象は、血管外漏出を含み、前記現在のリスク予測を提供するステップは、前記患者が前記血管外漏出を経験していると判定したことに応答して、前記少なくとも1つのプロセッサを用いて、流体注入システムを自動的に制御して前記流体注入を停止するステップをさらに含む、請求項13に記載の方法。 14. The method of claim 13, wherein the at least one adverse event includes an extravasation, and wherein providing the current risk prediction further includes, in response to determining that the patient is experiencing the extravasation, automatically controlling, using the at least one processor, a fluid injection system to stop the fluid injection. 前記少なくとも1つのセンサは、以下のセンサ、すなわち、画像捕捉デバイス；加速度計；歪みゲージ；全地球測位システム（GPS）；皮膚抵抗率またはコンダクタンスセンサ；心拍数モニタ；マイクロフォン；熱センサまたは温度センサ；パルスオキシメータ；水和センサ；線量計；超音波センサ；音響センサ；組織インピーダンス、筋電図（EMG）、および心電図（ECG）のうちの少なくとも1つを測定するように構成された1または複数の電極；マイクロ波センサ；機械インピーダンスセンサ；化学センサ；力センサまたは圧力センサ；あるいはそれらの任意の組み合わせのうちの少なくとも1つを含む、請求項13に記載の方法。 14. The method of claim 13, wherein the at least one sensor includes at least one of the following sensors: an image capture device; an accelerometer; a strain gauge; a global positioning system (GPS); a skin resistivity or conductance sensor; a heart rate monitor; a microphone; a thermal or temperature sensor; a pulse oximeter; a hydration sensor; a dosimeter; an ultrasonic sensor; an acoustic sensor; one or more electrodes configured to measure at least one of tissue impedance, an electromyogram (EMG), and an electrocardiogram (ECG); a microwave sensor; a mechanical impedance sensor; a chemical sensor; a force or pressure sensor; or any combination thereof. 前記少なくとも1つのプロセッサを用いて、前記現在のリスク予測に基づいて、（i）前記流体注入を停止する流体注入システム、および（ii）撮像動作のタイミングを調整する撮像システムのうちの少なくとも1つを自動的に制御するステップ
をさらに含む、請求項13に記載の方法。 14. The method of claim 13, further comprising: automatically controlling, with the at least one processor, at least one of: (i) a fluid injection system to stop the fluid injection; and (ii) an imaging system to adjust timing of imaging operations based on the current risk prediction.
JP2022566201A 2020-04-30 2021-04-30 Systems, devices and methods for protecting patient health for fluid infusion Pending JP2023523798A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063017942P 2020-04-30 2020-04-30
US63/017,942 2020-04-30
US202062704954P 2020-06-04 2020-06-04
US62/704,954 2020-06-04
US202062705613P 2020-07-07 2020-07-07
US62/705,613 2020-07-07
US202062706597P 2020-08-27 2020-08-27
US62/706,597 2020-08-27
PCT/US2021/030210 WO2021222771A1 (en) 2020-04-30 2021-04-30 System, device, and method for safeguarding wellbeing of patients for fluid injection

Publications (2)

Publication Number Publication Date
JP2023523798A JP2023523798A (en) 2023-06-07
JPWO2021222771A5 true JPWO2021222771A5 (en) 2024-05-13

Family

ID=75977857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566201A Pending JP2023523798A (en) 2020-04-30 2021-04-30 Systems, devices and methods for protecting patient health for fluid infusion

Country Status (7)

Country Link
US (3) US11896352B2 (en)
EP (1) EP4143840A1 (en)
JP (1) JP2023523798A (en)
CN (1) CN115485783A (en)
AU (1) AU2021264011A1 (en)
CA (3) CA3228205A1 (en)
WO (1) WO2021222771A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7260471B2 (en) * 2016-06-24 2023-04-18 ジョージア テック リサーチ コーポレイション Systems and methods for detecting IV infiltration
JP2023543877A (en) * 2020-09-30 2023-10-18 ベクトン・ディキンソン・アンド・カンパニー Systems, methods, and computer program products for vascular access device placement
EP4102517A1 (en) * 2021-06-11 2022-12-14 Siemens Healthcare GmbH Risk determination for a ct-examination
WO2023081279A1 (en) * 2021-11-03 2023-05-11 Amit Bahl Methods and systems for detecting intravascular device failure
WO2023159229A1 (en) 2022-02-21 2023-08-24 Bayer Healthcare Llc System, method and device for delivery of a therapeutic or diagnostic agent
WO2023212186A1 (en) 2022-04-29 2023-11-02 Bayer Healthcare Llc System, method, and computer program product for implementing a remote console for use in diagnostic imaging procedures
WO2024054586A1 (en) 2022-09-08 2024-03-14 Bayer Healthcare Llc Systems and methods for generating protocols embodying contrast and radiation dose management techniques

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US383858A (en) 1888-06-05 mepartland
US3156236A (en) 1961-12-07 1964-11-10 Cordis Corp Medical injector
US4610665A (en) 1983-01-18 1986-09-09 Terumo Kabushiki Kaisha Medical instrument
US5026348A (en) 1988-06-06 1991-06-25 The General Hospital Corporation Apparatus and method for the detection of IV catheter obstruction and extravasation
US5163928A (en) 1991-01-07 1992-11-17 Franklin Electronic Publishers, Incorporated Self-centering catheter
US5334141A (en) 1992-06-26 1994-08-02 Medrad, Inc. Extravasation detection system and apparatus
US5964703A (en) 1994-01-14 1999-10-12 E-Z-Em, Inc. Extravasation detection electrode patch
US6397098B1 (en) 1994-09-21 2002-05-28 Medrad, Inc. Data communication and control for medical imaging systems
US5651776A (en) 1995-03-22 1997-07-29 Angiodynamics, Inc. Luer-type connector
US5954668A (en) 1996-06-14 1999-09-21 Medrad, Inc. Extravasation detector using microwave radiometry
DE19859811C2 (en) 1998-12-23 2001-05-10 Hilekes Guido Contrast agent injection system
US6408204B1 (en) 1999-07-28 2002-06-18 Medrad, Inc. Apparatuses and methods for extravasation detection
US6339718B1 (en) 1999-07-30 2002-01-15 Medrad, Inc. Programmable injector control
US7047058B1 (en) 2001-02-06 2006-05-16 Medrad, Inc. Apparatuses, systems and methods for extravasation detection
US7308300B2 (en) 2001-05-30 2007-12-11 Acist Medical Systems, Inc. Medical injection system
DE60215668T2 (en) 2001-07-26 2007-08-30 Medrad, Inc. ELECTROMAGNETIC SENSORS FOR BIOLOGICAL TISSUE APPLICATIONS
US7122012B2 (en) 2001-07-26 2006-10-17 Medrad, Inc. Detection of fluids in tissue
US7563249B2 (en) 2002-12-20 2009-07-21 Medrad, Inc. Syringe having an alignment flange, an extending lip and a radial expansion section of reduced wall thickness
WO2004069153A2 (en) 2003-01-27 2004-08-19 Medrad, Inc. Apparatus, system and method for generating bubbles on demand
US7553294B2 (en) 2002-05-30 2009-06-30 Medrad, Inc. Syringe plunger sensing mechanism for a medical injector
US20040171923A1 (en) 2002-12-06 2004-09-02 Kalafut John F. Devices, systems and methods for improving vessel access
JP4511549B2 (en) 2003-10-24 2010-07-28 メドラッド インコーポレーテッド System for detecting fluid exchange and sensor device therefor
US7666169B2 (en) 2003-11-25 2010-02-23 Medrad, Inc. Syringe and syringe plungers for use with medical injectors
US8235949B2 (en) 2004-09-10 2012-08-07 Medrad, Inc. Application systems for use with medical devices
US7809430B2 (en) 2004-09-14 2010-10-05 Nemoto Kyorindo Co., Ltd. Leak detecting apparatus
US20060079842A1 (en) 2004-10-13 2006-04-13 Liebel-Flarsheim Company Powerhead control in a power injection system
US20060173360A1 (en) 2005-01-07 2006-08-03 Kalafut John F Method for detection and display of extravasation and infiltration of fluids and substances in subdermal or intradermal tissue
US20060211970A1 (en) 2005-03-16 2006-09-21 Sciulli Frank J Releasable application systems and releasable medical device systems
US7766883B2 (en) 2007-10-30 2010-08-03 Medrad, Inc. System and method for proportional mixing and continuous delivery of fluids
EP2532376B1 (en) 2006-02-09 2019-09-18 DEKA Products Limited Partnership Pumping fluid delivery systems using force application assembly
US8579884B2 (en) 2006-02-09 2013-11-12 Deka Products Limited Partnership Infusion pump assembly
US20090234226A1 (en) 2006-04-04 2009-09-17 Nemoto Kyorindo Co., Ltd. Chemical liquid injector
EP2012670B1 (en) 2006-04-19 2014-10-08 ACIST Medical Systems, Inc. Extravasation detection device
US7674244B2 (en) 2006-05-23 2010-03-09 Medrad, Inc. Devices, systems and methods for detecting increase fluid levels in tissue
US20080147147A1 (en) 2006-12-18 2008-06-19 Medrad, Inc. Vein locating device for vascular access procedures
EP2152337B1 (en) 2007-05-04 2013-04-17 Mallinckrodt LLC Methods for controlling medical fluid injections
US9333293B2 (en) 2007-05-09 2016-05-10 Acist Medical Systems, Inc. Injector device, method, and computer program product for detecting a vacuum within a syringe
EP2211941B1 (en) 2007-09-24 2018-11-21 Liebel-Flarsheim Company LLC Injection monitor
WO2009051995A1 (en) 2007-10-19 2009-04-23 Medrad, Inc. Methods for capicitance volume correction in fluid delivery systems
WO2009067200A2 (en) 2007-11-19 2009-05-28 Mallinckrodt Inc. Fluid delivery system with multi-dose fluid source
US9408971B2 (en) 2008-03-31 2016-08-09 Covidien Lp Self-capping syringe assembly with one-way valve
JP5485885B2 (en) 2008-06-24 2014-05-07 株式会社根本杏林堂 Chemical injection device, fluoroscopic imaging system having this chemical injection device, computer program of chemical injection device, and data processing method
US9421330B2 (en) * 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
JP5897798B2 (en) 2008-11-19 2016-03-30 株式会社根本杏林堂 Leak detection system
EP2735376B1 (en) 2009-07-24 2017-08-23 Bayer Healthcare LLC Syringe for a fluid injector system
JP5511409B2 (en) 2010-01-28 2014-06-04 株式会社根本杏林堂 Chemical injection system
CN103269737B (en) 2010-10-07 2017-06-06 麻省理工学院 Use the injecting method of servo-controlled needleless injector
CA2820557A1 (en) 2010-11-29 2012-06-07 Sanofi-Aventis Deutschland Gmbh Auto-injector device with a medicated module
US20120204997A1 (en) 2011-02-15 2012-08-16 Acist Medical Systems, Inc. Monitoring injector operation
CN103596608B (en) 2011-03-31 2017-05-17 株式会社根本杏林堂 Leakage detection sensor and drug infusion system
JP5882595B2 (en) 2011-03-31 2016-03-09 株式会社根本杏林堂 Leak detection sensor and chemical injection system
RU2618159C2 (en) 2011-05-12 2017-05-02 БАЙЕР ХелсКер ЛЛСи System of liquid administration with different systems of injection procedure control
EP2734253A1 (en) 2011-07-18 2014-05-28 Mallinckrodt LLC Injection system with capacitive sensing
US9326686B2 (en) 2012-03-12 2016-05-03 Ivwatch, Llc System and method for mitigating the effects of tissue blood volume changes to aid in diagnosing infiltration or extravasation in animalia tissue
US9995611B2 (en) 2012-03-30 2018-06-12 Icu Medical, Inc. Air detection system and method for detecting air in a pump of an infusion system
US9259527B2 (en) 2012-10-17 2016-02-16 Bayer Healthcare Llc Fluid delivery system with high and low pressure hand manifold
CN104869903B (en) 2012-12-19 2020-08-28 皇家飞利浦有限公司 X-ray controlled contrast agent injection
US9517305B2 (en) 2013-03-15 2016-12-13 Bayer Healthcare Llc Medical fluid injector
CN105636639B (en) 2013-10-18 2019-12-03 拜耳医药保健有限公司 Magnetic pressure set for fluid injector
IL302231A (en) 2014-01-10 2023-06-01 Bayer Healthcare Llc Single-use disposable set connector
US20160331896A1 (en) 2014-01-22 2016-11-17 Nemoto Kyorindo Co., Ltd. Imaging system and injecting apparatus
WO2015147217A1 (en) 2014-03-27 2015-10-01 株式会社根本杏林堂 Sensor pad kit for leak detection sensor, leak detection system, and chemical grouting system
WO2015150280A1 (en) 2014-04-02 2015-10-08 Grosse Wentrup David Infusion system and method for integrity monitoring of an infusion system
NZ726432A (en) 2014-04-25 2022-07-01 Bayer Healthcare Llc Syringe with rolling diaphragm
EP3185931A1 (en) 2014-08-26 2017-07-05 Debiotech S.A. Detection of an infusion anomaly
US9199033B1 (en) 2014-10-28 2015-12-01 Bayer Healthcare Llc Self-orienting syringe and syringe interface
NO2689315T3 (en) 2014-10-28 2018-04-14
RU2714926C2 (en) 2015-01-09 2020-02-21 БАЙЕР ХелсКер ЛЛСи Multiple fluid delivery system with multi-use disposable set and features thereof
US20160224750A1 (en) 2015-01-31 2016-08-04 The Board Of Trustees Of The Leland Stanford Junior University Monitoring system for assessing control of a disease state
KR20170120154A (en) 2015-02-27 2017-10-30 바이엘 헬쓰케어 엘엘씨 Quantification phantom for use with multiple imaging modalities
EP3285649A4 (en) 2015-04-24 2019-01-09 Bayer Healthcare LLC Syringe with rolling diaphragm
JP6552258B6 (en) 2015-05-01 2019-09-04 学校法人 岩手医科大学 Leak detection device
WO2017038575A1 (en) 2015-08-28 2017-03-09 株式会社根本杏林堂 Medicinal liquid injecting circuit, medicinal liquid injecting system provided with said medicinal liquid injecting circuit, and medical imaging system
US10398353B2 (en) 2016-02-19 2019-09-03 Covidien Lp Systems and methods for video-based monitoring of vital signs
WO2017152036A1 (en) 2016-03-03 2017-09-08 Bayer Healthcare Llc System and method for improved fluid delivery in multi-fluid injector systems
EP3525839B1 (en) 2016-10-17 2021-12-29 Bayer Healthcare LLC Fluid injector with syringe engagement mechanism
WO2019046267A1 (en) 2017-08-31 2019-03-07 Bayer Healthcare Llc Fluid injector system volume compensation system and method
AU2018323442B2 (en) 2017-08-31 2024-06-27 Bayer Healthcare Llc Fluid path impedance assessment for improving fluid delivery performance
CN110891630B (en) 2017-08-31 2022-04-26 拜耳医药保健有限公司 System and method for drive member positioning and fluid injector system mechanical calibration
EP3675931B1 (en) 2017-08-31 2021-08-11 Bayer Healthcare LLC Injector pressure calibration system and method
WO2019046259A1 (en) 2017-08-31 2019-03-07 Bayer Healthcare Llc System and method having transition phase in multi-phase injection protocol
CA3068544A1 (en) 2017-08-31 2019-03-07 Bayer Healthcare Llc Method for dynamic pressure control in a fluid injector system
CN112218668B (en) 2018-04-19 2023-07-18 拜耳医药保健有限公司 System and method for air detection in a fluid injector
WO2020046889A1 (en) 2018-08-28 2020-03-05 Bayer Healthcare Llc Fluid injector system with improved ratio performance
US20210220556A1 (en) 2018-08-28 2021-07-22 Bayer Healthcare Llc Fluid injector system, method of preventing fluid backflow, and computer program product
US11160570B2 (en) 2019-04-11 2021-11-02 Covidien Lp Aspiration flow sensor
CN114730625A (en) 2019-11-21 2022-07-08 拜耳医药保健有限责任公司 Systems and methods for delivering fluid using pressure-based motor control for fluid injector apparatus
US20220392602A1 (en) 2019-11-21 2022-12-08 Bayer Healthcare Llc System and method for user-configurable pressure limiting behavior for fluid injection devices
WO2021101939A1 (en) 2019-11-21 2021-05-27 Bayer Healthcare Llc System, method, and computer program product for occlusion detection and improved pressure limiting behavoir for fluid injector devices
WO2021108286A1 (en) 2019-11-25 2021-06-03 Bayer Healthcare Llc System and method utilizing an integrated camera with a fluid injector
US20230111299A1 (en) 2020-03-31 2023-04-13 Bayer Healthcare Llc System for air volume correction based on fluid pressure and flow rate
CA3185452A1 (en) 2020-06-02 2021-12-09 Bayer Healthcare Llc System, method, and computer program product for controlling a fluid injection system based on hydraulic resistance
CA3187431A1 (en) 2020-06-18 2021-12-23 Bayer Healthcare Llc In-line air bubble suspension apparatus for angiography injector fluid paths
WO2022265695A1 (en) 2021-06-17 2022-12-22 Bayer Healthcare Llc System and method for detecting fluid type in tubing for fluid injector apparatus

Similar Documents

Publication Publication Date Title
JP7257994B2 (en) A system for sensing physiological data, draining and analyzing body fluids
JP5235014B2 (en) Equipment for lymphatic system monitoring
US6863656B2 (en) Stress test devices and methods
US20190343445A1 (en) Systems, devices and methods for draining and analyzing bodily fluids
US20220079516A1 (en) Ultrasound-based closed-loop control of patient therapy
US20080108905A1 (en) System for sensing, diagnosing and treating physiological conditions and methods
JP2019063539A (en) Fluid pressure sensing assembly
CA3005447A1 (en) Systems, devices and methods for draining and analyzing bodily fluids
US20220273213A1 (en) Systems, devices and methods for draining and analyzing bodily fluids and assessing health
CA3005443A1 (en) Devices and methods for monitoring physiologic parameters
CN108095809B (en) A kind of puncture needle and drainage device for paracentesis pericardii
CA2595344A1 (en) Ambulatory medical device and method of communication between medical devices
JPWO2021222771A5 (en)
Paranjape et al. Use of a modified passive leg-raising maneuver to predict fluid responsiveness during experimental induction and correction of hypovolemia in healthy isoflurane-anesthetized pigs
Quispe et al. Auxiliary tests of autonomic functions
Valverde et al. Comparison of noninvasive cardiac output measured by use of partial carbon dioxide rebreathing or the lithium dilution method in anesthetized foals
JP2002301154A (en) Oxygen inhaling flow rate determination supporting system used for oxygen therapy
JP2005523762A (en) Needle insertion sensor
Hedriana Ultrasound measurement of fetal urine flow
JP2018528018A (en) Determination of gas dissolved in blood during extracorporeal circulation
US20240099624A1 (en) Systems, devices and methods for draining and analyzing bodily fluids, pressures and assessing health
Schauvliege et al. Comparison between lithium dilution and pulse contour analysis techniques for cardiac output measurement in isoflurane anaesthetized ponies: influence of different inotropic drugs
Foy Blood pressure monitoring.
TWI610660B (en) Personalized bladder care device
CN118176541A (en) System and method for controlling targeted infusion